Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Canadian National Railway Co. (CNI) vs GeneDx Holdings Corp (WGS) Price & Performance

Canadian National Railway Co.Trade
GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

Canadian National Railway Co. vs GeneDx Holdings Corp — how do they compare? Canadian National Railway Co. trades at $126.3 (market cap $76.28B), while GeneDx Holdings Corp trades at $82.71 (market cap $2.44B). The key difference: Canadian National Railway Co. is far larger — about 31.3× GeneDx Holdings Corp's market cap, and Canadian National Railway Co. pays a 2.06% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.

CNIWGS
Market Cap
$76.28B$2.44B
Sector
IndustrialsTechnology
52-Week High
$130.58$167.51
52-Week Low
$90.91$34.51
Enterprise Value
$92.31B$2.48B
Dividend Yield
2.06%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Canadian National Railway Co.

CNI trades at $126.29, up 0.91% on the day, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.50, and raised its full-year guidance, driven by record grain volumes and operational efficiency. Financials show solid profitability with a net income margin of 26.92% and ROE of 22.02%, though valuation ratios like P/E of 22.62 appear elevated.

The outlook is positive due to robust operational performance and raised guidance, but risks include stretched valuation, economic sensitivity, and competitive pressures. Analyst consensus is a Buy with a $152.38 price target, implying potential upside, though recent downgrades highlight valuation concerns.

GeneDx Holdings Corp

GeneDx Holdings Corp (WGS) trades at $82.39, up 5.79% in the past 24 hours, with a bullish technical signal and strong analyst support. The company reported Q2 2026 revenue of $114.4 million, beating guidance, and returned to adjusted profitability earlier than expected. However, net income remains negative at -$106 million for 2026, and the stock faces class action lawsuits with an August 3, 2026 deadline.

Outlook is mixed: bullish technicals and analyst consensus suggest upside to the $90 price target, but fundamental weaknesses and legal risks pose significant challenges. Investment opportunity hinges on sustained revenue growth and margin improvement, while risks include profitability pressures and litigation outcomes.

Returns comparison

Trailing returns across standard periods

About Canadian National Railway Co.

Canadian National's railway spans Canada from coast to coast and extends through Chicago to the Gulf of Mexico. In 2019, CN delivered almost 6 million carloads over its 19,600 miles of track. CN generated roughly CAD 14 billion in total revenue by hauling intermodal containers (25% of consolidated revenue), petroleum and chemicals (21%), grain and fertilizers (16%), forest products (12%), metals and mining (11%), automotive shipments (6%), and coal (4%). Other items constitute the remaining revenue.

Read more on CNI

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS